Somaliland Science Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Somaliland Science Reporter.

Press releases published on June 14, 2026

Jun. 14, 2026

Enterprise Integration Has Become the Modernization Bet Mid-Market Companies Underrate, Says APPSeCONNECT

Indeterminate EIN Presswire

Jun. 14, 2026

Gyeonggi Business and Science Accelerator Sets Off Global Scale-Up in Full Swing with the ‘1st Pan-Pan Day.’

Indeterminate EIN Presswire

Jun. 14, 2026

Venom AI Launches a Live Mentor That Turns AI Conversations Into Real Products

Indeterminate EIN Presswire

Jun. 14, 2026

Research Identifies 5 Best Restaurant POS Platforms Standing Out in Australia in 2026

Indeterminate EIN Presswire

Jun. 14, 2026

Holiday Ice, Inc. Highlights Why 2,500 lb Daily Ice Output Fits Mid-Size Food Processors

Indeterminate EIN Presswire

Jun. 14, 2026

P1Mitigators Unveils InsureFENCE℠ — First AI-Powered Fencing Insurance Scope Scanner

Indeterminate EIN Presswire

Jun. 14, 2026

Dyadica Launches Breakthrough Philolaus AI Driven Brand Strategy Program to Supercharge Brand Strategy and Management

Indeterminate EIN Presswire

Jun. 14, 2026

SumGeniusAI Launches AI Copilot and Knowledge Gaps for ChatGenius DM Automation

Indeterminate EIN Presswire

Jun. 14, 2026

Z-Text Bug Bounty Goes Live: 7 ZEC On-Chain to Anyone Who Breaks It

Indeterminate EIN Presswire

Jun. 14, 2026

Online Community Service For Probation

Indeterminate EIN Presswire

Jun. 14, 2026

Stake Launches its Referral Code SHIMA – 200% Bonus and 5% Cashback for New Users in 2026

Indeterminate GlobeNewswire

Jun. 14, 2026

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Indeterminate GlobeNewswire

Jun. 14, 2026

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Indeterminate GlobeNewswire

Jun. 14, 2026

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Indeterminate GlobeNewswire

Jun. 14, 2026

XM Announces Enhanced Trading Conditions and Opportunities for Global Traders - Featuring Partner Code 274PQ

Indeterminate GlobeNewswire